The Asia-Pacific Nuclear Medicine Market is expected to reach USD 4,274 million by the end of 2019 growing at a CAGR of around 16% from 2014 to 2019. Nuclear Medicine utilizes the radioisotope for application in diagnosis and treatment of diseases. The drugs containing radionuclides are said to be Radiopharmaceuticals. The uses in Radiological imaging include Magnetic Resonance Imaging (MRI), Computerized tomography (CT), Positron Emission Tomography (PET) and Single Proton Emission Tomography (SPECT).
The Nuclear Medicine for diagnostic purposes is gaining importance in Asia-Pacific region rapidly. There have been increased use of SPECT, PET, CT, MRI for diagnosis of cardiac diseases, Brain diseases, Cancer and many others. Nuclear medicine is being used for therapeutic purposes for treatment of Alzheimer’s disease, coronary heart diseases, bone metastasis and many other cancers. Nuclear Medicine for therapeutic purposes is being used for treatment of cancers, different medical conditions affecting thyroid gland, and scar – tissue removal.
The increasing incidence and prevalence of Cancer, Thyroidal diseases, endocrinal diseases and cardiac Ailments, rise in applications of SPECT and PET with advancement of technology and growing awareness amongst physicians and public awareness for better healthcare, emerging economies in Asia-Pacific and developing healthcare industry are key factors driving the growth of Nuclear medicine market. However, Short half-life of Radiopharmaceuticals, high capital investment required for development, stringent regulatory guidelines and unawareness amongst a large patient population are factors turning out to be restraints for this market.
The Asia-Pacific Nuclear Medicine Market have been segmented based on, type and application. The segmentation based on type of Product have been segmented based on diagnostic market and therapeutic market, wherein, the Diagnostics market have been further subdivided into SPECT radioisotopes that include Technetium-993, Thallium-201, Iodine-123, Gallium and PET radioisotopes that include Rubidium-82, Flourine-18 and the therapeutics category have been segmented into Alpha emitters (Radium-223), Beta Emitters(includes Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (includes iodine-125, Cesium-131, Palladium-103, & Iridium-192). The segmentation based on application have been similarly subdivided based on diagnostic and therapeutic application. The Diagnostic application includes the application of SPECT and PET in Cardiology, Neurology, Oncology and others. The therapeutic applications includes application in Oncology, Thyroid, Endocrinology and various other therapeutic areas.
The Asia-Pacific geographical segmentation have been categorized into China, India, Japan, Australia, New Zealand and South Korea. There is expected a good growth in Indian and Chinese market due to fast growing economy and recent health initiatives being taken up by the government. Further upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications.
Currently, the segment of diagnostics holds the largest share in Nuclear Medicine Market in which again SPECT has the largest share. In the segmentation based on type, the Beta Emitters hold the largest share. The increasing imaging technologies, potential radioisotopes in pipeline, increasing neurological applications and cyclotron based production are becoming key opportunities for growth of Nuclear Medicine Market. The Key Players in this Nuclear Medicine market are Mallinckrodt, Lantheus Medical Imaging, IBA Group, Triad Isotope, Siemens Healthcare, NTP Radioisotopes, Cardinal Health, GE Healthcare, Nordion, Inc., and Fujifilm Holding Corporation.
Key deliverables of the study